Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 19:6:e5655.
doi: 10.7717/peerj.5655. eCollection 2018.

Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity score-matched analysis

Chia-Che Wu #  1 , Shau-Hsuan Li #  1 , Hung-I Lu  2 , Chien-Ming Lo  2 , Yu-Ming Wang  3 , Shang-Yu Chou  3 , Yen-Hao Chen  1   4   5
Affiliations

Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity score-matched analysis

Chia-Che Wu et al. PeerJ. .

Abstract

Introduction: The present study investigated the crucial role of inflammation-based prognostic scores in locally advanced cervical esophageal squamous cell carcinoma (ESCC) patients who underwent curative concurrent chemoradiotherapy (CCRT).

Methods: There were 411 ESCC patients enrolled, including 63 cervical ESCC patients. Using the propensity score matching method, 63 thoracic ESCC patients were matched to the 63 cervical ESCC patients. The inflammation-based prognostic scores included the neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), albumin level, c-reactive protein (CRP) level, modified Glasgow prognostic score (mGPS), and CRP/albumin ratio. The chi-square test and Kaplan-Meier method were used for categorical variable data and overall survival, respectively. A Cox regression model was performed for univariate and multivariable analyses.

Results: With respect to cervical ESCC, NLR ≥ 2.5 (P = 0.019), PLR ≥ 103 (P = 0.013), CRP value >10 mg/l (P = 0.040), mGPS ≥ 1 (P = 0.040), and CRP/albumin ratio ≥ 9.5 (P = 0.033) were significant predictors of worse overall survival (OS) in the univariate analysis. In a multivariable analysis, PLR ≥ 103 (P = 0.010, HR: 2.66, 95% CI [1.27-5.58]) and mGPS ≥ 1 (P = 0.030, HR: 2.03, 95% CI [1.07-3.86]) were the independent prognostic parameters of worse OS. The prognostic value of these biomarkers in the matched thoracic ESCC patients was similar and compatible with the results in the cervical ESCC group in the univariate and multivariable analyses.

Conclusions: Our study suggests that these inflammation-based prognostic scores are helpful in clinical practice, and PLR and mGPS may predict the prognosis for locally advanced cervical ESCC patients who receive curative CCRT.

Keywords: Concurrent chemoradiotherapy; Esophageal cancer; Inflammation; Propensity score matching; Squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare there are no competing interests.

Figures

Figure 1
Figure 1. Algorithm for identifying locally advanced cervical and thoracic esophageal squamous cell carcinoma (ESCC) patients.
Figure 2
Figure 2. Comparison of overall survival curves of cervical esophageal squamous cell carcinoma patients according to different inflammation-based prognostic scores.
(A) Neutrophil lymphocyte ratio (NLR). (B) Platelet lymphocyte ratio (PLR) (C) Modified Glasgow prognostic score (mGPS). (D) CRP/albumin ratio.
Figure 3
Figure 3. Comparison of overall survival curves of thoracic esophageal squamous cell carcinoma patients according to different inflammation-based prognostic scores.
(A) Neutrophil lymphocyte ratio (NLR). (B) Platelet lymphocyte ratio (PLR) (C) Modified Glasgow prognostic score (mGPS). (D) CRP/albumin ratio.
See this image and copyright information in PMC

References

    1. Balkwill FR. The chemokine system and cancer. Journal of Pathology. 2012;226:148–157. doi: 10.1002/path.3029. - DOI - PubMed
    1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–545. doi: 10.1016/S0140-6736(00)04046-0. - DOI - PubMed
    1. Chen MF, Yang YH, Lai CH, Chen PC, Chen WC. Outcome of patients with esophageal cancer: a nationwide analysis. Annals of Surgical Oncology. 2013;20:3023–3030. doi: 10.1245/s10434-013-2935-4. - DOI - PubMed
    1. Chen YH, Lu HI, Chien CY, Lo CM, Wang YM, Chou SY, Su YY, Shih LH, Li SH. Treatment outcomes of patients with locally advanced synchronous esophageal and head/neck squamous cell carcinoma receiving curative concurrent chemoradiotherapy. Scientific Reports. 2017b;7:41785. doi: 10.1038/srep41785. - DOI - PMC - PubMed
    1. Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Huang CH, Shih LH, Chen SW, Li SH. The clinical impact of supraclavicular lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy. PLOS ONE. 2018;13:e0198800. doi: 10.1371/journal.pone.0198800. - DOI - PMC - PubMed

LinkOut - more resources